Published in PLoS One on January 24, 2015
Sulfated glycosaminoglycans in protein aggregation diseases. Glycoconj J (2017) 0.77
RNA Contaminates Glycosaminoglycans Extracted from Cells and Tissues. PLoS One (2016) 0.75
How Glycosaminoglycans Promote Fibrillation of Salmon Calcitonin. J Biol Chem (2016) 0.75
The Neuroprotective Role of Protein Quality Control in Halting the Development of Alpha-Synuclein Pathology. Front Mol Neurosci (2017) 0.75
Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol (2002) 82.19
The roles of intracellular protein-degradation pathways in neurodegeneration. Nature (2006) 9.77
Biochemical and molecular investigations in respiratory chain deficiencies. Clin Chim Acta (1994) 4.93
Lysosomal membrane permeabilization in cell death. Oncogene (2008) 4.40
Genetic animal models of Parkinson's disease. Neuron (2010) 3.86
Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol (2008) 3.35
Pathogenic lysosomal depletion in Parkinson's disease. J Neurosci (2010) 2.73
Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP. Proc Natl Acad Sci U S A (2002) 2.64
Distinct roles in vivo for the ubiquitin-proteasome system and the autophagy-lysosomal pathway in the degradation of α-synuclein. J Neurosci (2011) 2.53
Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation. J Neurochem (2007) 2.32
Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. Neurobiol Dis (2009) 1.90
Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc Natl Acad Sci U S A (2013) 1.88
Interaction of arginine-rich peptides with membrane-associated proteoglycans is crucial for induction of actin organization and macropinocytosis. Biochemistry (2007) 1.83
Improved and simple micro assay for sulfated glycosaminoglycans quantification in biological extracts and its use in skin and muscle tissue studies. Glycobiology (2003) 1.77
Heparin and other glycosaminoglycans stimulate the formation of amyloid fibrils from alpha-synuclein in vitro. Biochemistry (2002) 1.71
Cathepsin D expression level affects alpha-synuclein processing, aggregation, and toxicity in vivo. Mol Brain (2009) 1.62
Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity. Mol Brain (2008) 1.61
Chondroitin-4-sulfation negatively regulates axonal guidance and growth. J Cell Sci (2008) 1.61
Cathepsin D is the main lysosomal enzyme involved in the degradation of alpha-synuclein and generation of its carboxy-terminally truncated species. Biochemistry (2008) 1.50
Distinct region-specific alpha-synuclein oligomers in A53T transgenic mice: implications for neurodegeneration. J Neurosci (2010) 1.49
Selective effects of sodium chlorate treatment on the sulfation of heparan sulfate. J Biol Chem (1999) 1.42
The lysosomal-mitochondrial axis theory of postmitotic aging and cell death. Chem Biol Interact (2006) 1.38
Physicochemical characteristics of the glycosaminoglycan-lysosomal enzyme interaction in vitro. A model of control of leucocytic lysosomal activity. Biochem J (1976) 1.33
Alpha-synuclein up-regulation and aggregation during MPP+-induced apoptosis in neuroblastoma cells: intermediacy of transferrin receptor iron and hydrogen peroxide. J Biol Chem (2004) 1.24
Parkinson's disease and related alpha-synucleinopathies are brain amyloidoses. Ann N Y Acad Sci (2003) 1.18
Developmental regulation of the sulfation profile of chondroitin sulfate chains in the chicken embryo brain. J Biol Chem (1997) 1.15
Inhibition of leucocytic lysosomal enzymes by glycosaminoglycans in vitro. Biochem J (1975) 1.15
Ubiquitination of alpha-synuclein and autophagy in Parkinson's disease. Autophagy (2008) 1.10
α-Synuclein and protein degradation systems: a reciprocal relationship. Mol Neurobiol (2012) 1.08
Pathogenesis of Parkinson's disease: emerging role of molecular chaperones. Trends Mol Med (2009) 1.06
Genetic and pathological links between Parkinson's disease and the lysosomal disorder Sanfilippo syndrome. Mov Disord (2011) 0.95
Effects of 1-methyl-4-phenylpyridinium on isolated rat brain mitochondria: evidence for a primary involvement of energy depletion. J Neurochem (1994) 0.89
Age-related changes in rat myocardium involve altered capacities of glycosaminoglycans to potentiate growth factor functions and heparan sulfate-altered sulfation. J Biol Chem (2012) 0.86
A synthetic glycosaminoglycan mimetic (RGTA) modifies natural glycosaminoglycan species during myogenesis. J Cell Sci (2005) 0.85
α-Synuclein ubiquitination and novel therapeutic targets for Parkinson's disease. CNS Neurol Disord Drug Targets (2014) 0.84
Hyperstimulation of macropinocytosis leads to lysosomal dysfunction during exposure to methamphetamine in SH-SY5Y cells. Brain Res (2012) 0.84
Mouse N-acetylgalactosamine 4-sulfotransferases-1 and -2. Molecular cloning, expression, chromosomal mapping and detection of their activity with GalNAcbeta1-4GlcNAcbeta1-octyl. J Biochem (2003) 0.83
Upregulation of cathepsin D in the caudate nucleus of primates with experimental parkinsonism. Mol Neurodegener (2011) 0.83
Glycosaminoglycans, protein aggregation and neurodegeneration. Curr Protein Pept Sci (2011) 0.81
In vitro aggregation assays for the characterization of α-synuclein prion-like properties. Prion (2014) 0.81
Insights on a new path of pre-mitochondrial apoptosis regulation by a glycosaminoglycan mimetic. Cell Death Differ (2009) 0.79
Glycosylation-related gene expression in prion diseases: PrPSc accumulation in scrapie infected GT1 cells depends on beta-1,4-linked GalNAc-4-SO4 hyposulfation. J Biol Chem (2005) 0.78
Hydrogen peroxide as a potential mediator of the transcriptional regulation of heparan sulphate biosynthesis in keratinocytes. Cell Mol Biol Lett (2008) 0.77
Self-evolving oxidative stress with identifiable pre- and postmitochondrial phases in PC12 cells. J Neurosci Res (2012) 0.76